Incyte (INCY) AI Stock Analysis

• Market Cap: $18.07B
• Dividend Yield: N/A
• Average Volume (3M): 1.75M
• Price to Earnings (P/E): 15.0
• Beta (1Y): 0.51
• Revenue Growth: 18.09%
• EPS Growth: 3563.21%
• Country: US
• Employees: 2,617
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.80
• Shares Outstanding: 199,014,480
• 10 Day Avg. Volume: 1,606,901
• 30 Day Avg. Volume: 1,752,829
• PEG Ratio: <0.01
• Price to Book (P/B): 3.73
• Price to Sales (P/S): 3.75
• P/FCF Ratio: 14.23
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 2.97
• Enterprise Value/Gross Profit: 3.23
• Enterprise Value/Ebitda: 8.66
• 1Y Price Target: $110.53
• Price Target Upside: 21.76% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 17
• EPS Forecast (FY): 7.48
• Revenue Forecast (FY): $5.59B

• Rating: 75 Outperform
• Price Target: $109.00 ▲(20.07% Upside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is driven primarily by strong financial strength (low leverage and a major 2025 profitability/cash-flow rebound) and a generally positive earnings-call outlook with solid 2026 growth guidance and pipeline breadth. Offsetting these are weak technical momentum (below key moving averages with negative MACD) and event-driven/regulatory timing risk from the Zynyz CRL, while valuation appears reasonable on a ~15 P/E but with no dividend support.

Positive Factors

Conservative balance sheet

Very low leverage and a strengthened equity base give Incyte durable financial flexibility to fund late-stage trials, absorb manufacturing or regulatory delays, and pursue M&A or partnerships without near-term refinancing risk. This underpins capital allocation through 2026 and beyond.

Improved cash generation

Close alignment of free cash flow with net income in 2025 indicates stronger earnings quality and internal funding capacity. Reliable FCF supports funding multiple pivotal trials and launches, reduces dependence on external capital, and improves runway to execute the company’s multi‑asset strategy over the next 2–6 months.

Diversifying revenue and constructive guidance

Guidance and accelerating non‑Jakafi franchises (Opsilora, hematology/oncology) show the business moving from Jakafi concentration toward multiple revenue pillars. This diversification trajectory, if executed, materially reduces single-product risk and supports sustainable growth over the medium term.

Negative Factors

Jakafi concentration and LOE risk

Jakafi remains the single largest revenue source, so patent expiry and eventual generic entry create a multi‑year cliff risk. Success of numerous launches and approvals is required to offset that decline; failure or slower uptake of replacements would materially pressure revenue and cash flow beyond 2026.

Opsilora PN clinical setback

A failed pivotal PN readout and the regulator’s request for another trial delay approval and commercialization timelines, raise incremental costs, and reduce near‑term revenues from this indication. It also signals program‑specific clinical risk that can ripple into formulary and pricing negotiations.

Rising R&D and execution burden

Substantial and rising R&D spend to support ~14 pivotal trials increases cash burn and execution complexity. The concentrated investment across many programs magnifies regulatory, enrollment, and manufacturing risks; missed readouts or delays would pressure margins and defer the expected revenue diversification.

Incyte Business Overview & Revenue Model

Company Description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

How the Company Makes Money

Incyte generates revenue primarily through the sale of its proprietary products, with Jakafi being the most significant contributor to its income. The company also earns revenue from collaboration agreements and licensing deals with other pharmaceutical companies, which often include upfront payments, milestone payments based on the achievement of development and regulatory goals, and royalties on sales of partnered products. Additionally, Incyte's strategic partnerships enhance its research capabilities and broaden its product offerings, allowing it to tap into new markets and therapeutic areas, further diversifying its revenue streams.

Incyte Financial Statement Overview

Summary

Strong overall fundamentals anchored by a very conservative balance sheet (very low leverage) and a sharp 2025 rebound in profitability (high gross margin and solid net margin). Cash generation strengthened meaningfully in 2025 with good earnings-to-FCF alignment, but multi-year volatility in earnings and cash conversion reduces confidence in durability.

Income Statement

Revenue growth has been consistently positive from 2021–2025, with a notable acceleration in 2025 (up ~6.8% vs. ~0.1% in 2024). Profitability is strong in 2025 with very high gross margins (~93%) and a solid net margin (~25%), rebounding sharply from the near-breakeven 2024 net margin (~0.8%). The main weakness is earnings volatility across the period (losses in 2020, strong profits in 2021, softer 2024, then a large rebound in 2025), which lowers confidence in durability versus steadier peers.

Balance Sheet

The balance sheet is conservatively positioned with extremely low leverage (debt-to-equity consistently around ~0.7%–1.8%, and ~0.7% in 2025), providing ample financial flexibility. Equity has also expanded meaningfully versus 2024, and returns on equity are strong in 2025 (~25%), reflecting the earnings rebound. The key weakness is that profitability (and therefore returns on equity) has been inconsistent year-to-year, which can make the balance-sheet strength look less impactful during weaker profit periods.

Cash Flow

Cash generation is strong in 2025, with operating cash flow and free cash flow both sharply higher and free cash flow growth solidly positive (~13%). Free cash flow broadly tracks earnings well in 2025 (free cash flow is ~96% of net income), suggesting good earnings quality. The weakness is volatility: 2024 operating cash flow was relatively low versus net income (about 20%), and both operating and free cash flow were negative in 2020, indicating cash conversion can swing materially across years.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.14B	4.24B	3.70B	3.39B	2.99B
Gross Profit	4.70B	3.86B	3.38B	3.14B	2.80B
EBITDA	1.76B	408.16M	919.43M	599.64M	630.20M
Net Income	1.29B	32.62M	597.60M	340.66M	948.58M
Balance Sheet
Total Assets	6.96B	5.44B	6.78B	5.84B	4.93B
Cash, Cash Equivalents and Short-Term Investments	3.58B	2.16B	3.66B	3.24B	2.35B
Total Debt	69.43M	43.54M	38.29M	41.46M	44.82M
Total Liabilities	1.80B	2.00B	1.59B	1.47B	1.16B
Stockholders Equity	5.17B	3.45B	5.19B	4.37B	3.77B
Cash Flow
Free Cash Flow	1.35B	249.07M	449.00M	892.11M	568.48M
Operating Cash Flow	1.41B	335.34M	496.49M	969.94M	749.49M
Investing Cash Flow	-102.61M	157.52M	-207.68M	-78.54M	-207.70M
Financing Cash Flow	101.04M	-2.02B	-20.03M	-794.00K	6.18M

Incyte Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 90.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INCY, the sentiment is Negative. The current price of 90.78 is below the 20-day moving average (MA) of 96.45, below the 50-day MA of 100.52, and above the 200-day MA of 89.67, indicating a neutral trend. The MACD of -2.52 indicates Positive momentum. The RSI at 33.24 is Neutral, neither overbought nor oversold. The STOCH value of 16.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INCY.

Incyte Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTHR	85 Outperform	$22.98B	16.17	19.30%	―	13.50%	17.16%
EXEL	76 Outperform	$10.72B	12.10	36.88%	―	9.93%	54.33%
INCY	75 Outperform	$18.07B	14.98	29.15%	―	18.09%	3563.21%
BMRN	68 Neutral	$10.41B	32.67	5.82%	―	12.31%	60.21%
GMAB	66 Neutral	$15.62B	19.82	14.32%	―	24.98%	127.06%
ASND	57 Neutral	$13.62B	-50.22	127.54%	―	103.32%	47.55%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Incyte Corporate Events

Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion

On February 27, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter to Incyte for its supplemental Biologics License Application seeking to expand Zynyz’s use to adult patients with metastatic non-small cell lung cancer in combination with platinum-based chemotherapy. The filing was backed by positive Phase 3 POD1UM-304 data reported in December 2024.

The FDA cited regulatory compliance issues at Catalent Indiana, the third-party fill-finish facility owned by Novo Nordisk and referenced in the application, as the sole obstacle to approval, without raising concerns about Zynyz’s efficacy, safety or its drug substance manufacturer. Incyte is collaborating with the FDA and Catalent Indiana to resolve the manufacturing site findings and enable a potential resubmission, delaying expansion of Zynyz’s NSCLC label but preserving the therapy’s clinical profile in this indication.

The most recent analyst rating on (INCY) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on Incyte stock, see the INCY Stock Forecast page.

Incyte Board Member Hervé Hoppenot Retires

On December 10, 2025, Hervé Hoppenot announced his retirement from Incyte Corporation’s Board of Directors, effective immediately. Mr. Hoppenot, who previously served as Chairman and CEO, had been a board member since 2014.

The most recent analyst rating on (INCY) stock is a Hold with a $84.00 price target. To see the full list of analyst forecasts on Incyte stock, see the INCY Stock Forecast page.